Towards Healthcare
Middle East and Africa Cell and Gene Therapy Market to Grow at 19.17% CAGR til...

Middle East and Africa Cell and Gene Therapy Market Growth Path

Projections indicate that, the Middle East and Africa cell and gene therapy market will increase from USD 4.52 billion in 2024 to USD 26.12 billion by 2034, experiencing a CAGR of 19.17% over the next 10 years. The burgeoning biotechnology sector and the growing demand for personalized medicines drive the market.

Content

  • Insight Code: 6281
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The Middle East and Africa cell and gene therapy market in 2025 is valued at USD 5.4 billion and is projected to climb to USD 26.12 billion by 2034, with a CAGR of 19.17% over the forecast period.

The Middle East and Africa cell and gene therapy market includes seven segments by therapy type, by therapeutic area, by vector/delivery type (for gene therapy), by cell source (for cell therapy), by manufacturing scale & service, by end-user, and by region.

Some key players include CureLeads, Opal Biopharma, Novartis, and Thermo Fisher Scientific.

CGT treats numerous disorders, including ADA-SCID, congenital blindness, hemophilia, Leber congenital amaurosis, and lysosomal storage diseases.

Gene therapy refers to the introduction of new genetic material into cells to restore the function of proteins.
Any Questions